Russian Federation: These 24 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: capsaicin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: Russian Federation Patent 2,005,134,984
Patent Title: ТЕРАПЕВТИЧЕСКИЙ ПЛАСТЫРЬ С ПОЛИСИЛОКСАНОВОЙ МАТРИЦЕЙ, СОДЕРЖАЩЕЙ КАПСАИЦИН

QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.

This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA

See drug price trends for QUTENZA.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.

Generic name: capsaicin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: Russian Federation Patent 2,349,315
Patent Title: ТЕРАПЕВТИЧЕСКИЙ ПЛАСТЫРЬ С ПОЛИСИЛОКСАНОВОЙ МАТРИЦЕЙ, СОДЕРЖАЩЕЙ КАПСАИЦИН (THERAPEUTICAL PLASTER WITH POLYSILOXANE MATRIX CONTAINING CAPSAICIN)

QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.

This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA

See drug price trends for QUTENZA.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Russian Federation Patent 2,005,132,453
Patent Title: СОСТАВЫ, ВЫЗЫВАЮЩИЕ ПОТЕРЮ ВЕСА

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-five patent family members in forty-two countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Russian Federation Patent 2,350,327
Patent Title: СОСТАВЫ, ВЫЗЫВАЮЩИЕ ПОТЕРЮ ВЕСА (COMPOUNDS CAUSING WEIGHT LOSS)

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-five patent family members in forty-two countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Russian Federation Patent 2,005,137,276
Patent Title: ЗАМЕЩЕННЫЕ ДИГИДРОХИНАЗОЛИНЫ С ПРОТИВОВИРУСНЫМИ СВОЙСТВАМИ

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Russian Federation Patent 2,360,912
Patent Title: ЗАМЕЩЕННЫЕ ДИГИДРОХИНАЗОЛИНЫ С ПРОТИВОВИРУСНЫМИ СВОЙСТВАМИ (SUBSTITUTED DIHYDROQUINAZOLINES HAVING ANTIVIRAL PROPERTIES)

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Russian Federation Patent 2,005,139,526
Patent Title: ИММУНОДЕПРЕССАНТНЫЕ СОЕДИНЕНИЯ И КОМПОЗИЦИИ

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Russian Federation Patent 2,009,132,108
Patent Title: ИММУНОДЕПРЕССАНТНЫЕ СОЕДИНЕНИЯ И КОМПОЗИЦИИ

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Russian Federation Patent 2,405,768
Patent Title: ИММУНОДЕПРЕССАНТНЫЕ СОЕДИНЕНИЯ И КОМПОЗИЦИИ (IMMUNOSUPPRESSIVE COMPOUNDS AND COMPOSITIONS)

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,006,103,280
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,008,152,033
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,352,581
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА (INSULIN DERIVATIVES)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,518,460
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА (INSULIN DERIVATIVES)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,006,103,280
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА

TRESIBA is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,008,152,033
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА

TRESIBA is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,352,581
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА (INSULIN DERIVATIVES)

TRESIBA is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,518,460
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА (INSULIN DERIVATIVES)

TRESIBA is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,006,103,280
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,008,152,033
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,352,581
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА (INSULIN DERIVATIVES)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Russian Federation Patent 2,518,460
Patent Title: ПРОИЗВОДНЫЕ ИНСУЛИНА (INSULIN DERIVATIVES)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and forty patent family members in thirty-nine countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: cabazitaxel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Russian Federation Patent 2,006,113,122
Patent Title: АЦЕТОНОВЫЙ СОЛЬВАТ ДИМЕТОКСИДОЦЕТАКСЕЛА И СПОСОБ ЕГО ПОЛУЧЕНИЯ

JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has ninety-eight patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.

Generic name: cabazitaxel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Russian Federation Patent 2,342,373
Patent Title: АЦЕТОНОВЫЙ СОЛЬВАТ ДИМЕТОКСИДОЦЕТАКСЕЛА И СПОСОБ ЕГО ПОЛУЧЕНИЯ (ACETONE SOLVATE OF DIMETHOXY DOCETAXEL AND METHOD OF OBTAINING IT)

JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has ninety-eight patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.

Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Russian Federation Patent 2,006,118,786
Patent Title: ТВЕРДЫЙ ПРЕПАРАТ

DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT

See drug price trends for DUETACT.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Russian Federation Patent 2,359,661
Patent Title: ТВЕРДЫЙ ПРЕПАРАТ (SOLID PREPARATION)

DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT

See drug price trends for DUETACT.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Russian Federation Patent 2,006,116,414
Patent Title: ПЕПТИДНАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОПИЛЕНГЛИКОЛЬ,ЯВЛЯЮЩАЯСЯ ОПТИМАЛЬНОЙ ДЛЯ ИЗГОТОВЛЕНИЯ И ПРИМЕНЕНИЯ В ИНЪЕКЦИОННЫХ УСТРОЙСТВАХ

SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Russian Federation Patent 2,421,238
Patent Title: ПЕПТИДНАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОПИЛЕНГЛИКОЛЬ, ЯВЛЯЮЩАЯСЯ ОПТИМАЛЬНОЙ ДЛЯ ИЗГОТОВЛЕНИЯ И ПРИМЕНЕНИЯ В ИНЪЕКЦИОННЫХ УСТРОЙСТВАХ (PEPTIDE COMPOSITION CONTAINING PROPYLENE GLYCOL OPTIMAL FOR MANUFACTURING AND APPLICATION IN INJECTION DEVICES)

SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Russian Federation Patent 2,006,116,414
Patent Title: ПЕПТИДНАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОПИЛЕНГЛИКОЛЬ,ЯВЛЯЮЩАЯСЯ ОПТИМАЛЬНОЙ ДЛЯ ИЗГОТОВЛЕНИЯ И ПРИМЕНЕНИЯ В ИНЪЕКЦИОННЫХ УСТРОЙСТВАХ

VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Russian Federation Patent 2,421,238
Patent Title: ПЕПТИДНАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОПИЛЕНГЛИКОЛЬ, ЯВЛЯЮЩАЯСЯ ОПТИМАЛЬНОЙ ДЛЯ ИЗГОТОВЛЕНИЯ И ПРИМЕНЕНИЯ В ИНЪЕКЦИОННЫХ УСТРОЙСТВАХ (PEPTIDE COMPOSITION CONTAINING PROPYLENE GLYCOL OPTIMAL FOR MANUFACTURING AND APPLICATION IN INJECTION DEVICES)

VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Russian Federation Patent 2,006,122,599
Patent Title: СПОСОБ ИЗГОТОВЛЕНИЯ ТВЕРДОГО, ОРАЛЬНО ПРИМЕНЯЕМОГО ФАРМАЦЕВТИЧЕСКОГО СОСТАВА

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Russian Federation Patent 2,009,127,302
Patent Title: СПОСОБ ИЗГОТОВЛЕНИЯ ТВЕРДОГО, ОРАЛЬНО ПРИМЕНИМОГО ФАРМАЦЕВТИЧЕСКОГО СОСТАВА

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Russian Federation Patent 2,379,036
Patent Title: СПОСОБ ИЗГОТОВЛЕНИЯ ТВЕРДОГО, ОРАЛЬНО ПРИМЕНИМОГО ФАРМАЦЕВТИЧЕСКОГО СОСТАВА (METHOD FOR MAKING SOLID ORAL PHARMACEUTICAL COMPOSITION)

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Russian Federation Patent 2,493,850
Patent Title: СПОСОБ ИЗГОТОВЛЕНИЯ ТВЕРДОГО, ОРАЛЬНО ПРИМЕНИМОГО ФАРМАЦЕВТИЧЕСКОГО СОСТАВА (METHOD FOR PREPARING SOLID, ORAL PHARMACEUTICAL FORMULATION)

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Russian Federation Patent 2,007,122,410
Patent Title: КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОСНОВУ ИЛИ ПОКРЫТИЕ ДЛЯ ЗАМЕДЛЕННОГО ВЫСВОБОЖДЕНИЯ И АНТАГОНИСТ NMDA-РЕЦЕПТОРА, СПОСОБ ВВЕДЕНИЯ ТАКОГО NMDA-АНТАГОНИСТА СУБЪЕКТУ

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Russian Federation Patent 2,007,140,348
Patent Title: СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Russian Federation Patent 2,404,750
Patent Title: КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОСНОВУ ИЛИ ПОКРЫТИЕ ДЛЯ ЗАМЕДЛЕННОГО ВЫСВОБОЖДЕНИЯ И АНТАГОНИСТ NMDA РЕЦЕПТОРА, СПОСОБ ВВЕДЕНИЯ ТАКОГО NMDA АНТАГОНИСТА СУБЪЕКТУ (COMPOSITION CONTAINING BASE OR COAT FOR MODERATED RELEASE AND ANTAGONIST OF NMDA RECEPTOR, METHOD FOR INTRODUCTION OF SUCH NMDA ANTAGONIST TO INDIVIDUAL)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Russian Federation Patent 2,008,122,929
Patent Title: ГЕТЕРОЦИКЛИЧЕСКИЕ МОДУЛЯТОРЫ ТРАНСПОРТЕРОВ АТФ-СВЯЗЫВАЮЩЕЙ КАССЕТЫ

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Russian Federation Patent 2,012,123,372
Patent Title: ГЕТЕРОЦИКЛИЧЕСКИЕ МОДУЛЯТОРЫ ТРАНСПОРТЕРОВ АТФ-СВЯЗЫВАЮЩЕЙ КАССЕТЫ

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Russian Federation Patent 2,016,150,386
Patent Title: ГЕТЕРОЦИКЛИЧЕСКИЕ МОДУЛЯТОРЫ ТРАНСПОРТЕРОВ АТФ-СВЯЗЫВАЮЩЕЙ КАССЕТЫ

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Russian Federation Patent 2,463,303
Patent Title: ГЕТЕРОЦИКЛИЧЕСКИЕ МОДУЛЯТОРЫ ТРАНСПОРТЕРОВ АТФ-СВЯЗЫВАЮЩЕЙ КАССЕТЫ (HETEROCYCLIC MODULATORS OF ATP-BINDING CARTRIDGE TRANSPORTER)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Russian Federation Patent 2,608,610
Patent Title: ГЕТЕРОЦИКЛИЧЕСКИЕ МОДУЛЯТОРЫ ТРАНСПОРТЕРОВ АТФ-СВЯЗЫВАЮЩЕЙ КАССЕТЫ (HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Russian Federation Patent 2,765,714
Patent Title: ГЕТЕРОЦИКЛИЧЕСКИЕ МОДУЛЯТОРЫ ТРАНСПОРТЕРОВ АТФ-СВЯЗЫВАЮЩЕЙ КАССЕТЫ (HETEROCYCLIC MODULATORS OF TRANSPORTERS OF AN ATP-BINDING CASSETTE)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,133,902
Patent Title: ТВЕРДЫЕ ПРЕПАРАТИВНЫЕ ФОРМЫ ОСПЕМИФЕНА

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Russian Federation Patent 2,011,112,362
Patent Title: ТВЕРДЫЕ ПРЕПАРАТИВНЫЕ ФОРМЫ ОСПЕМИФЕНА

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Russian Federation Patent 2,423,113
Patent Title: ТВЕРДЫЕ ПРЕПАРАТИВНЫЕ ФОРМЫ ОСПЕМИФЕНА (SOLID PREPARATIVE FORMS OF OSPEMIFENE)

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Russian Federation Patent 2,675,624
Patent Title: ТВЕРДЫЕ ПРЕПАРАТИВНЫЕ ФОРМЫ ОСПЕМИФЕНА (SOLID FORMULATIONS OF OSPEMIFENE)

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: fostemsavir tromethamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,136,390
Patent Title: ПИПЕРАЗИНОВЫЕ ПРОЛЕКАРСТВА И ЗАМЕЩЕННЫЕ ПИПЕРИДИНОВЫЕ ПРОТИВОВИРУСНЫЕ АГЕНТЫ

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

Generic name: fostemsavir tromethamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Russian Federation Patent 2,374,256
Patent Title: ПИПЕРАЗИНОВЫЕ ПРОЛЕКАРСТВА И ЗАМЕЩЕННЫЕ ПИПЕРИДИНОВЫЕ ПРОТИВОВИРУСНЫЕ АГЕНТЫ (PIPERAZINE PRODRUGS AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS)

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,136,090
Patent Title: ГАЛЕНОВЫ СОСТАВЫ ОРГАНИЧЕСКИХ СОЕДИНЕНИЙ

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Russian Federation Patent 2,009,138,446
Patent Title: ГАЛЕНОВЫ СОСТАВЫ ОРГАНИЧЕСКИХ СОЕДИНЕНИЙ

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Russian Federation Patent 2,011,135,405
Patent Title: ТВЕРДАЯ ПЕРОРАЛЬНАЯ ЛЕКАРСТВЕННАЯ ФОРМА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ (ВАРИАНТЫ)

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Russian Federation Patent 2,384,328
Patent Title: ГАЛЕНОВЫ СОСТАВЫ ОРГАНИЧЕСКИХ СОЕДИНЕНИЙ (HALENIC COMPOSITIONS OF ORGANIC COMPOUNDS)

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Russian Federation Patent 2,438,661
Patent Title: ГАЛЕНОВЫ СОСТАВЫ ОРГАНИЧЕСКИХ СОЕДИНЕНИЙ (GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS)

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Russian Federation Patent 2,480,210
Patent Title: ТВЕРДАЯ ПЕРОРАЛЬНАЯ ЛЕКАРСТВЕННАЯ ФОРМА И СПОСОБ ЛЕЧЕНИЯ (ORAL SOLID DOSAGE FORM AND METHOD OF TREATING)

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: etonogestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,136,913
Patent Title: УСТРОЙСТВО ДЛЯ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ВИДИМОЕ В РЕНТГЕНОВСКИХ ЛУЧАХ

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

Generic name: etonogestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Russian Federation Patent 2,384,347
Patent Title: УСТРОЙСТВО ДЛЯ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ВИДИМОЕ В РЕНТГЕНОВСКИХ ЛУЧАХ (X-RAY VISIBLE DRUG DELIVERY DEVICE)

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 07, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,132,180
Patent Title: КРИСТАЛЛИЧЕСКИЙ ПОЛИМОРФ БАЗЕДОКСИФЕН АЦЕТАТА

DUAVEE is a drug marketed by Wyeth Pharms. There are two patents protecting this drug.

This drug has twenty-two patent family members in twenty countries.

See drug price trends for DUAVEE.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,143,664
Patent Title: СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: carfilzomib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Russian Federation Patent 2,384,585
Patent Title: СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ (ENZYME INHIBITING COMPOUNDS)

KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS

See drug price trends for KYPROLIS.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,143,840
Patent Title: ИНГАЛЯТОР

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Russian Federation Patent 2,363,501
Patent Title: ИНГАЛЯТОР (INHALER)

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,143,840
Patent Title: ИНГАЛЯТОР

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Russian Federation Patent 2,363,501
Patent Title: ИНГАЛЯТОР (INHALER)

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Russian Federation Patent 2,330,845
Patent Title: СТАБИЛЬНЫЙ КРИСТАЛЛ 4-ОКСОХИНОЛИНОВОГО СОЕДИНЕНИЯ (STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND)

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has eighty-four patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Russian Federation Patent 2,006,145,357
Patent Title: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ZD6474

CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.

This drug has one hundred and forty-two patent family members in forty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Russian Federation Patent 2,383,343
Patent Title: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ZD6474 (PHRAMACEUTICAL COMPOSITIONS CONTAINING ZD6474)

CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.

This drug has one hundred and forty-two patent family members in forty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.